Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or other factors?
Community PollStarted
Do you recommend adjuvant immunotherapy and/or PARP inhibition in early-stage endometrial cancers for whom you are already recommending adjuvant chemotherapy?
51 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Gynecologic Oncology · Alliance Cancer Specialists, PC
Answered on
I hesitate to offer the chemo/IO combination to patients with stage I disease as this is likely an overtreatment. The majority of the patients who require chemotherapy for stage I disease are those with serous and carcinosarcoma histology. Most of those patients are not even MMRd. It is unclear what...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
Answered on
Because high risk Stage I patients were not included in these trials (serous, carcinsarcoma, clear cell, mixed histologies), I don't typically recommend the addition of IO to chemotherapy for early stage disease. We will likely see this data for the dMMR early stage patients in future trials.
Join for free or sign in to see the full answer